Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV trial

niversity of Oxford0 sites10,000 target enrollmentApril 29, 2020

Overview

No summary available.

Registry

who.int

Start Date

April 29, 2020

End Date

TBD

Last Updated

5 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•1\.Participant is willing and able to give informed consent for participation in the study
•2\.Agrees not to self\-medicate with chloroquine, hydroxychloroquine or other potential antivirals
•3\.Adults (exact age is dependent on countries) less than 70 years old at the time of consent). See Appendix F for UK specific information
•4\.Not previously diagnosed with COVID\-19
•5\.Not currently symptomatic with an ARI
•6\.Participant works in a facility where there are cases of either proven or suspected COVID\-19
•7\.Possesses an internet\-enabled smartphone (Android or iOS)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes

•1\. Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4\-aminoquinolines
•2\. Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, known creatinine clearance \< 10 ml/min
•3\. Already taking chloroquine, hydroxychloroquine or 4\-aminoquinolines
•4\. Taking a concomitant medication described in section 8\.5
•5\. Known retinal disease
•6\. Inability to be followed up for the trial period
•7\. Known prolonged QT syndrome (however ECG is not required at baseline)
•8\. Prior diagnosis of porphyria
•9\. Known pregnancy or women who are actively trying to become pregnant